ArticleBMC rheumatology2026
Real-world effectiveness and safety of upadacitinib in Japanese patients with rheumatoid arthritis: impact of age, renal function, and low-dose therapy.
Article in BMC rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Japanese evidence on Janus kinase inhibitors for rheumatoid arthritis: a narrative review of risk-optimized use.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUpadacitinib (UPA) is an important therapeutic option for rheumatoid arthritis (RA), but evidence in older adults and patients with renal impairment remains limited. This study evaluated the real-world effectiveness and safety of UPA in Japanese patients with RA, including older adults and those with renal impairment. PATIENTS AND
methodsThis multicenter retrospective study included 112 patients with RA who received UPA (7.5 or 15 mg/day), with clinical outcomes assessed up to 52 weeks based on medical record review. Effectiveness was assessed using the Disease Activity Score 28–erythrocyte sedimentation rate (DAS28-ESR), Clinical Disease Activity Index (CDAI), and Health Assessment Questionnaire–Disability Index (HAQ-DI). Safety was evaluated based on adverse events and laboratory findings. Predictors of response were explored using multivariable regression, and prespecified subgroup analyses were performed by age (≥ 75 vs. <75 years), renal function (eGFR < 60 vs. ≥60 mL/min/1.73 m²), and UPA dose (7.5 vs. 15 mg/day).
resultsAt week 52, 87.5% of patients continued UPA, and 62.5% achieved DAS28-ESR remission (< 2.6). Significant improvements in DAS28-ESR and CDAI were observed and maintained through week 52. Similar improvements in disease activity were observed in patients aged ≥ 75 years and in those with renal impairment. Clinical response was associated with baseline disease activity, anti-cyclic citrullinated peptide antibody levels, rheumatoid factor titers, and prior biologic or targeted synthetic DMARD use. The 7.5 mg/day regimen was more frequently prescribed to older patients and those with renal impairment.
conclusionUPA demonstrated sustained effectiveness and acceptable safety across clinically important subgroups of Japanese patients with RA, including older adults and those with renal impairment. These findings suggest the feasibility of individualized treatment strategies; however, dose comparisons should be interpreted cautiously given physician-driven prescribing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.